 Marta Batus
Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 9 | 2023 | 76 | 3.130 |
Why?
| | Antineoplastic Agents | 8 | 2016 | 244 | 1.960 |
Why?
| | Lung Neoplasms | 14 | 2021 | 745 | 1.810 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 13 | 2021 | 372 | 1.510 |
Why?
| | Soft Tissue Neoplasms | 2 | 2022 | 28 | 1.050 |
Why?
| | Molecular Targeted Therapy | 3 | 2013 | 35 | 0.970 |
Why?
| | Metastasectomy | 1 | 2021 | 5 | 0.860 |
Why?
| | Bone Neoplasms | 3 | 2022 | 118 | 0.810 |
Why?
| | Antibodies, Monoclonal | 4 | 2016 | 293 | 0.790 |
Why?
| | Immunotherapy | 3 | 2021 | 75 | 0.760 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2019 | 378 | 0.680 |
Why?
| | Medical Oncology | 1 | 2016 | 37 | 0.570 |
Why?
| | Chemoradiotherapy | 4 | 2019 | 72 | 0.540 |
Why?
| | Retrospective Studies | 16 | 2023 | 3835 | 0.480 |
Why?
| | ErbB Receptors | 4 | 2018 | 79 | 0.470 |
Why?
| | Prognosis | 9 | 2023 | 1011 | 0.460 |
Why?
| | Melanoma | 1 | 2013 | 64 | 0.450 |
Why?
| | Humans | 27 | 2023 | 32988 | 0.340 |
Why?
| | Neoplasm Staging | 10 | 2022 | 457 | 0.330 |
Why?
| | Survival Rate | 5 | 2021 | 443 | 0.320 |
Why?
| | Mutation | 3 | 2021 | 464 | 0.300 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2018 | 207 | 0.280 |
Why?
| | Neutrophils | 2 | 2023 | 139 | 0.260 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2018 | 81 | 0.250 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2016 | 244 | 0.240 |
Why?
| | Receptor, IGF Type 1 | 2 | 2013 | 21 | 0.230 |
Why?
| | Sarcoma, Synovial | 1 | 2022 | 3 | 0.220 |
Why?
| | Quinazolines | 2 | 2012 | 28 | 0.220 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2021 | 42 | 0.210 |
Why?
| | Female | 16 | 2021 | 18423 | 0.210 |
Why?
| | Male | 15 | 2021 | 17726 | 0.210 |
Why?
| | Pneumonectomy | 1 | 2021 | 94 | 0.200 |
Why?
| | Lung | 1 | 2021 | 179 | 0.200 |
Why?
| | Autoantibodies | 1 | 2021 | 119 | 0.190 |
Why?
| | Adenocarcinoma | 3 | 2018 | 231 | 0.190 |
Why?
| | Middle Aged | 11 | 2021 | 11219 | 0.190 |
Why?
| | Treatment Outcome | 8 | 2021 | 4036 | 0.170 |
Why?
| | Inflammation Mediators | 1 | 2018 | 97 | 0.160 |
Why?
| | Survival Analysis | 5 | 2021 | 372 | 0.150 |
Why?
| | Palliative Care | 2 | 2015 | 158 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 2 | 2018 | 58 | 0.140 |
Why?
| | Neoplasm Metastasis | 2 | 2013 | 120 | 0.130 |
Why?
| | Gene Dosage | 2 | 2012 | 26 | 0.130 |
Why?
| | Adult | 7 | 2022 | 9848 | 0.130 |
Why?
| | Radiotherapy, Conformal | 1 | 2014 | 24 | 0.120 |
Why?
| | Aged | 10 | 2019 | 10542 | 0.120 |
Why?
| | Cancer Vaccines | 1 | 2013 | 16 | 0.120 |
Why?
| | Angiogenesis Inhibitors | 1 | 2013 | 23 | 0.120 |
Why?
| | Neoplasms | 1 | 2016 | 280 | 0.120 |
Why?
| | Forecasting | 1 | 2013 | 136 | 0.110 |
Why?
| | Weight Gain | 1 | 2012 | 75 | 0.110 |
Why?
| | Follow-Up Studies | 5 | 2018 | 2053 | 0.110 |
Why?
| | PTEN Phosphohydrolase | 1 | 2011 | 13 | 0.110 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2022 | 40 | 0.110 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 51 | 0.100 |
Why?
| | Gene Amplification | 1 | 2010 | 24 | 0.100 |
Why?
| | Child, Preschool | 1 | 2013 | 798 | 0.100 |
Why?
| | Pyrimidines | 1 | 2010 | 26 | 0.100 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2010 | 9 | 0.100 |
Why?
| | Xanthine Dehydrogenase | 1 | 2010 | 7 | 0.100 |
Why?
| | Rectal Neoplasms | 1 | 2010 | 29 | 0.100 |
Why?
| | Adolescent | 2 | 2016 | 2687 | 0.100 |
Why?
| | Young Adult | 2 | 2016 | 2287 | 0.100 |
Why?
| | Lymphocytes | 2 | 2023 | 116 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2010 | 126 | 0.090 |
Why?
| | Piperazines | 1 | 2010 | 96 | 0.090 |
Why?
| | United States | 1 | 2016 | 2632 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 368 | 0.090 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 8 | 0.080 |
Why?
| | Child | 1 | 2013 | 1634 | 0.080 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2007 | 7 | 0.080 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2007 | 8 | 0.080 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2007 | 15 | 0.080 |
Why?
| | Receptor, ErbB-2 | 1 | 2007 | 47 | 0.080 |
Why?
| | Carcinoma, Large Cell | 2 | 2018 | 18 | 0.070 |
Why?
| | Animals | 2 | 2013 | 5371 | 0.070 |
Why?
| | Prospective Studies | 2 | 2023 | 2002 | 0.070 |
Why?
| | Neoadjuvant Therapy | 2 | 2019 | 62 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 216 | 0.060 |
Why?
| | Etoposide | 2 | 2015 | 64 | 0.060 |
Why?
| | Carboplatin | 2 | 2015 | 54 | 0.060 |
Why?
| | Paclitaxel | 2 | 2015 | 79 | 0.060 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 17 | 0.060 |
Why?
| | Lymphocyte Count | 1 | 2023 | 38 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2018 | 5249 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2007 | 435 | 0.060 |
Why?
| | Time-to-Treatment | 1 | 2022 | 37 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2022 | 57 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2022 | 102 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2021 | 44 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2021 | 24 | 0.050 |
Why?
| | Observer Variation | 1 | 2021 | 142 | 0.050 |
Why?
| | Cohort Studies | 2 | 2015 | 2077 | 0.050 |
Why?
| | Mesna | 1 | 2019 | 3 | 0.040 |
Why?
| | Ifosfamide | 1 | 2019 | 11 | 0.040 |
Why?
| | Patient Selection | 1 | 2021 | 261 | 0.040 |
Why?
| | Organ Sparing Treatments | 1 | 2019 | 11 | 0.040 |
Why?
| | Doxorubicin | 1 | 2019 | 60 | 0.040 |
Why?
| | Leg | 1 | 2019 | 55 | 0.040 |
Why?
| | Arm | 1 | 2019 | 83 | 0.040 |
Why?
| | Proteomics | 1 | 2018 | 90 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 899 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2017 | 96 | 0.040 |
Why?
| | Taxoids | 1 | 2016 | 17 | 0.040 |
Why?
| | Deoxycytidine | 1 | 2016 | 36 | 0.040 |
Why?
| | Time Factors | 1 | 2022 | 1873 | 0.040 |
Why?
| | Body Weight | 1 | 2017 | 167 | 0.040 |
Why?
| | Radiation Pneumonitis | 1 | 2015 | 4 | 0.040 |
Why?
| | Hemoptysis | 1 | 2015 | 9 | 0.040 |
Why?
| | Esophagitis | 1 | 2015 | 11 | 0.040 |
Why?
| | Cough | 1 | 2015 | 13 | 0.040 |
Why?
| | Chest Pain | 1 | 2015 | 23 | 0.040 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2015 | 20 | 0.040 |
Why?
| | Dyspnea | 1 | 2015 | 39 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2015 | 44 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2015 | 228 | 0.030 |
Why?
| | Mobility Limitation | 1 | 2015 | 99 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2014 | 147 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 77 | 0.030 |
Why?
| | Diet | 1 | 2015 | 228 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 11 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2015 | 515 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2012 | 471 | 0.020 |
Why?
| | Benzamides | 1 | 2010 | 19 | 0.020 |
Why?
| | Colectomy | 1 | 2010 | 32 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 449 | 0.020 |
Why?
| | Biopsy | 1 | 2010 | 277 | 0.020 |
Why?
| | Quality of Life | 1 | 2015 | 747 | 0.020 |
Why?
| | Smoking | 1 | 2010 | 206 | 0.020 |
Why?
| | Signal Transduction | 1 | 2012 | 590 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2008 | 76 | 0.020 |
Why?
| | Risk Assessment | 1 | 2011 | 814 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2007 | 132 | 0.020 |
Why?
|
|
Batus's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|